Abstract. Hepatoid adenocarcinoma (HAC) is a rare and aggressive cancer subtype with a poor prognosis under metastatic conditions. Currently, there is no specific chemotherapy treatment protocol for advanced stages of the disease. This review evaluates two cases of HAC of gastric cardia with synchronous liver metastasis, which were successfully treated by chemotherapy with cisplatin (25 mg/m 2 each day) (day 1 to day 3) and etoposide (100 mg/m 2 ) (day 1 to day 3), every three weeks. A structured literary evaluation and reviewed pertinent articles are additionally presented to analyse the different approaches for the treatment of metastatic HAC (mHAC). The two described case reports demonstrated good partial responses to treatment and one of the two patients exhibited a good prognosis after a 9-year follow-up. A total of 20 case reports concerning the use of chemotherapy in mHAC were presented in the literature, 11 of which were regarding gastric HACs. The two aforementioned cases result in a total of 22 reports, 11 of which exhibited objective responses to chemotherapy, 8 patients demonstrated a partial response and 3 a complete response. The cisplatin-based regimen concerned 55% (12/22) patients and enabled 9 (75%) to exhibit a partial or complete response. A total of three patients exhibited a good prognosis in the long-term follow-up, all of them treated with a cisplatin-based regimen. It was demonstrated that the usual digestive regimens were not efficient in the treatment of HAC. In the absence of prospective trials, it may be hypothesized that cisplatin-based chemotherapy may be the most efficient first-line treatment in mHAC, with a 75% patient response, in accordance with the literature and follow-up cases.
Introduction
Hepatoid adenocarcinoma (HAC) represents approximately 0.2 to 0.8% of diagnosed gastric cancer (1). Ishikura et al defined HAC as extrahepatic tumor with hepatocyte differentiation and potentially increased α-fetoprotein (AFP) secretion (2) . HAC diagnosis is mainly histological and is characterized by large and polygonal hepatocyte-like cells with intense eosinophil cytoplasm and big central nucleus. HAC is mainly located in oesophagus and stomach, however other sites were also described (3) . According to a Chinese analysis, which includes a total of 180 gastric HACs from 62 different cases reports, the 3-year survival rate was only of 7.36% and the median survival time of 10 months (1). Another analysis including 31 gastric HAC patients described that: i) 87% of them exhibited an increased secretion of AFP serum level; ii) 55% had a locoregional synchronous node extension; and iii) 25% had synchronous metastatic, especially hepatic. An overexpression of AFP was detected by immunohistochemistry (IHC) in 90.3% of cases (4) . Conversely, Nagai et al showed that in 46% of HAC patients, any increase of AFP secretion was observed. Therefore, they proposed a novel description of HAC as an extrahepatic tumor with typical hepatocyte cells with or without AFP secretion (5) . Importantly, HAC must not be confounded with classical gastric adenocarcinoma, which can be associated with AFP overexpression, and having a better prognosis. Indeed, gastric HAC prognosis is poorer than classical histological types ones (4, 6) . Currently, the treatment of metastatic HAC (mHAC) remains not elucidated. Herein, we report two case-reports of mHAC patients. Moreover, through a pertinent review of the literature, we aim to analyse the different current therapeutic approaches for mHAC.
Materials and methods
We have performed a PRISMA-compliant systematic review of literature concerning the use of chemotherapy in mHAC (7) . Inclusion criteria for articles published from January 2001 to October 2016 were: i) mHAC; ii) treated by chemotherapy; and iii) with an evaluation of the response. ii) an icterus; iii) a paraneoplasic fever; and iv) a painful massive hepatomegaly. The laboratory investigation showed a biological chronic inflammation with LDH 25 times upper limit of normal (ULN), ASAT 2 ULN, and icteric cholestasis with total bilirubin at 120 µmol/l. Carcinoembryonic antigen (CEA) and CA 19-9 were normal, but serum AFP was elevated to 2,600 ng/ml. An oesogastroduodenoscopy discovered an ulcerated cardial tumoral lesion. Ultrasound scanning and computed tomography (CT) scans found three lesions in the right liver. A histopathologic examination of the cardia biopsy showed an ulcered HAC of the cardia, with tubulopapillary contingents. It was composed of large cells, with large nucleus, eosinophilic cytoplasm, and few hyaline balls. The periodic acid-Schiff (PAS) coloration, as well as the IHC of Hep Par antibodies, was negative. The histological examination of the hepatic biopsy showed the same HAC with the same cellular features, but with more necrosis aspects. The IHC study revealed CK19 positive (+), CK7 negative (-), CD10-, Chromogranine-, and Anti-synaptophysine negative cells. A systemic chemotherapy was delivered associating cisplatin 25 mg/m 2 with etoposide 100 mg/m 2 each day, day 1 to day 3, every 3 weeks. After one cycle, an impressive clinical improvement was notified with a decrease of abdominal pains and an extinction of hepatomegaly, with a straight decrease of icteric cholestasis although the AFP level was enhanced to 6,900 ng/ml. After 3 cycles, CT scans showed a good partial response on the liver metastasis and on the cardia lesion, confirmed after 6 cycles with a reduction of more than 80% of the size of liver metastasis. Moreover, the serum AFP levels were normalized. The Positron Emission Tomography (PET), realised two months after the end of chemotherapy, showed a complete metabolic gastric response and the persistence of two lesions in the segment VIII. The oesogastroduodenoscopy revealed an inflammatory cardia with complete histopathologic responses. After a one-year follow-up, a radical surgery associating gastrectomy and right hepatotectomy was decided by pluridisciplinary committee, and carried out. The patient was still alive, in complete remission at the last CT scan, more than 9 years after his diagnosis (Tables I and II; 
case 1).
Second case report. A 60 year-old French woman was admitted to the emergency ward in December 2014 for insomnia-related pains in her right hypochondrias, associated with anorexia, asthenia and a lose of weight of 3 kg in one month. Gastro-duodenal ulcer was notified in her digestive antecedents. The physical examination found a hepatomegaly and epigastric pains on the palpation. The laboratory investigation found ASAT 2 ULN, LDH to 7 ULN, and a non-icteric cholestasis. CT scans showed a tumor in the cardia extended to the low-oesophagus and greater curvature, numerous liver metastasis, up to 7 cm, with hypervascularization and necrotic center in arterial phase. In Magnetic Resonance Imaging (MRI), cardia tumor and hepatic metastasis appeared hyper-intense in T2 and diffusion sequence, with peripheral arterial enhancement (ring-shape) without washout. PET revealed an intense hypermetabolism of the liver metastasis and primary lesion (Fig. 2) . With particularly features in CT scans, tumoral markers have been analysed: 76,000 ng/ml for AFP, 176 IU/ml for CEA, and normal CA19-9. Oesogastroduodenoscopy showed an infiltrated ulceration of 4 cm on low-oesophagus and cardia on the third of the curvature. The histopathologic examination confirmed a HAC: round cells with big nuclei not much nucleolated, occasionally associated with a very dense chromatin, an eosinophile cytoplasm, but without intracytoplasmic hyaline globules as evaluated by PAS. As revealed by IHC studies, tumors were found KL1 positive (+), Glypican+, Glutamine Synthetase+, CK5-6 low, Hep Par antibodies low, CK20 negative (-), CK5-, AFP negative, Betacatenine-, Synaptophysin-, and P63 or Oestrogen receptors negative.
A systemic chemotherapy was delivered associating cisplatin 25 mg/m 2 with etoposide 100 mg/m 2 each day, day 1 to day 3, every 3 weeks, with a rapid decrease of pain, after the first cycle, although an initial increase of tumoral markers was observed (Fig. 3) . The first evaluation after 3 cycles by PET showed a metabolic complete response on the primary oesogastric lesion and metabolic partial response on the metastatic liver lesions (Fig. 2) . After 6 cycles, persistence of complete response was confirmed on the primary lesion, but an increase in size and intensity of liver metastasis was observed. A maintenance therapy by oral etoposid was administrated, but stopped 3 months later due to marker's increase. Nowadays, PET scan confirmed a hepatic progression with appearance of hypermetabolism on the left lower paratracheal nodes, without any relapse in oesogastric junction. A second line treatment with carboplatin and etoposid was carried out leading to a novel decrease of AFP levels before observing any progression (Fig. 3) . Finally, a third treatment by XELIRI (capecitabin and irinotecan) was administrated, without any efficiency. The patient died after 23 months-follow-ups (Tables I and II; case 2).
Results
Only one retrospective Korea cohort of 13 mHAC was found in our study with: i) one partial response reported with 5-fluoruracil (5-FU) associated with cisplatin; and ii) a second one with cisplatin-paclitaxel in second line (8) . Nevertheless, the others patients received different chemotherapy regimens. Therefore, as the nature of the treatment for each patients remained unknown, this cohort was excluded for the final analysis. Moreover, we have reported 2 colon, 2 lung, 2 pancreas, 1 bladder, 1 peritoneal, 1 mediastinum mHACs and 11 gastric mHACs (Tables I and III, especially with sorafenib treatment). Including our two case reports, the median age of the diagnosis was 56 years. Patients (73%) were male, 63% (14/22) and 72% (16/22) exhibited liver metastasis and synchrone metastasis, respectively. IHC AFP study was positive in 75% of cases (15/20) . When increased, the average AFP serum level was of 16,597 ng/ml. An initial surgery was carried out in 41% of cases (9/22). 11/22 BOR were observed with chemotherapy. Among them, 8/22 were partial responses and 3/22 complete ones. The complete response concerned 3 Japanese male patients with gastric HAC and liver metastasis. 55% (12/22) of the patients received a cisplatin-based regimen, whose 9/12 had partial or complete responses. Among partial or complete response of all case reports, 9/11 (81%) had a cisplatin-based chemotherapy. One another partial response was observed with a triple combined therapy: mitomycin-C, doxorubicin and 5-fluorouracil (Table II; case 8) .
Three patients were still alive with a follow-up superior to one year; these 3 patients were under Cisplatin-based chemotherapy regimen (Table II; cases 1, 7 and 14) . Finally, BioR was observed in 14 of 16 evaluable patients and AFP serum levels were normalized in 4 of 15 included patients of our review (Table II; cases 1, 4, 7 and 8).
In addition, 4 patients were treated by sorafenib in literature (Table III) . One of them, presenting a lung mHAC, also received an additional lung-chemotherapy regimen (Table III; case 22) (12) . Three other patients were treated in monotherapy, which permitted a greater stability of the disease (Table III; cases 19, 20 and 21) .
Discussion
Based on our investigation, we assume to describe the first two case reports of mHAC treated by cisplatin-etoposid as first-line chemotherapy leading to major partial and complete responses considering the primitive lesion. Indeed, we report a complete biological response: after a nine-year follow-up, we consider the patient to be completely treated from mHAC (described as the first case report). The treatment efficiency seems to be mostly due to cisplatin as we could detect a recurrence on the liver metastasis under oral etoposid in the case 2. As the maximal dose of administrated cisplatin had to be taken into account, this was preventing an additional cisplatin regimen in case 2. As described in case 2, other chemotherapy regimens appeared as inefficient as second and third lines treatment.
The review of literature is very limited and very few articles concerning the treatment of mHACs were reported. Lots of articles had to be excluded because no data regarding neither the kind of used chemotherapy nor its response were described. Therefore, these results had to be carefully interpreted and analysed. Indeed, as it is only an analysis of retrospective cases report, we cannot avoid some publication bias. In addition, the dose and schedules of chemotherapy administration were often not described in literature. Our results revealed a partial or complete response in 11 cases reports whom 81% had a Cisplatin-based regimen. Only one case, treated by cisplatin-etoposide-5-FU, can be identified as an efficient treatment with a long follow-up.
In our sense, cisplatin is probably the most interesting regimen to treat mHACs. These results were strongly correlated with ex vivo studies. Indeed, in a xenograft model of AFP-producing gastric cancer, mitomycin-C and cisplatin treatments might be effective to induce suppression of tumor growth, whereas 5-FU, doxorubicin, and epirubicin were shown as inefficient (13) . In our review, two complete responses have been observed with a cisplatin-based regimen or mitomycin-C regimen. Other usual chemotherapies carried out in digestive cancer as irinotecan, oxaliplatin, gemcitabine or 5-FU, are appearing as inefficient in mHAC (Table II; cases 11, 13, 15  and 17) .
Concerning targeted therapies, we do not possess full information. We can suppose that sorafenib which is the reference treatment in non-operable hepatocellular carcinoma could be a treatment option in HAC since they have similar histological features. An interesting progression free survival was reported in our review (Table III) . In addition, an analysis of peritoneal mHAC in a 21-year-old man, showed a strong activation of the epidermal growth factor, and of the kinases ERK1 and AKT1 (14) . Performing genome sequencing could be interesting in order to understand the molecular biology underlying mHAC (not described in the present time). In our cases, histopathological material was old or little biopsy materials, which is a strong limit to carry out a next sequencing generation.
Concerning non-gastric mHAC, we have stated only 2/7 partial responses in a lung and mediastinum primitive, and no objective responses in the two cases of colorectal HACs treated by a combined therapy composed of FOLFOX (oxaliplatin and 5-FU) plus bevacizumab, or FOLFIRI (irinotecan and 5-FU) plus bevacizumab (Table II; cases 11 and 17,  respectively) . No objective responses were related in a pancreatic HAC treated by gemcitabine. Consequently, traditional regimens seem to be not efficiency in mHAC. Cisplatin-based regimen seems to be the best option in non-gastric primitive HAC. Moreover radical surgery of primitive lesion or residual Table III BOR, best overall response; BioR, biological response; OS, overall survival; ULN, under limit of normal; PR, partial response; SD, stability disease; NA, not available.
lesion could be ever considered and discussed again in case of good and durable response in mHACs as reported in the case 1.
In conclusion, HAC represents a very rare and aggressive subtype of cancer defined as extrahepatic tumor with hepatocyte differentiation and potentially an increased AFP secretion. Currently, the treatment of mHAC remains not elucidated. We reported two cases of patients with mHAC successfully treated by chemotherapy with cisplatin and etoposide as first line leading to complete response. One of them is still alive after more than 9 years. In the absence of prospective trials in this rare cancer, we assume that cisplatin-based chemotherapy regimen could be the best first-line treatment in mHAC and considering as well our real-life experience as in view of literature, with 81% of response. Since the data of genome-wide analysis in cancers, it might be useful to provide some information with next generation sequencing in HAC, in order to find efficient target therapies.
